LEIDEN, NETHERLANDS -- (MARKET WIRE) -- April 03, 2007 -- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that it has been granted an important patent by the United States Patent and Trademark Office. The patent covers the manufacturing of influenza vaccines using Crucell’s PER.C6® cell line technology. With this new patent Crucell considerably strengthened its PER.C6® patent portfolio in this field. The newly granted patent provides additional years of patent protection for the use of the PER.C6® technology in the influenza field.
